Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 50.7 kDa. The protein migrates as 57-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Mouse FOLR1 Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
The purity of Mouse FOLR1 Protein, Fc Tag (Cat. No. FO1-M5254) is more than 90% and the molecular weight of this protein is around 100-125 kDa verified by SEC-MALS.
Immobilized Folic acid -BSA at 5 μg/mL (100 μL/well) can bind Mouse FOLR1 Protein, Fc Tag (Cat. No. FO1-M5254) with a linear range of 0.1-1 ng/mL (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Folinic Acid | FTHF | Approved | Anemia; Autism Spectrum Disorder; Down Syndrome; Rectal Neoplasms; Diarrhea; Vitamin B 12 Deficiency; Colorectal Neoplasms | Details | ||||||
Pafolacianine Sodium | Pteroyl-L-Tyr-S0456; OTL-38; EC-17; OTL-0038 | Approved | On Target Laboratories Inc | Cytalux | United States | Ovarian Neoplasms | On Target Laboratories Inc | 2021-11-29 | Ovarian Neoplasms; Inflammatory Bowel Diseases; Arthritis, Rheumatoid; Neoplasms; Breast Neoplasms; Pituitary Neoplasms; Lung Neoplasms | Details |
Mirvetuximab soravtansine | M9346-Asulfo-SPDB-DM4; IMGN-853 | Approved | Immunogen Inc | United States | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms | Immunogen Inc | 2022-11-14 | Ovarian Neoplasms; Solid tumours; Cystadenoma, Serous; Carcinoma, Ovarian Epithelial; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Uterine Neoplasms; Carcinosarcoma; Adenocarcinoma | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Noscapine-folate conjugate | Phase 1 Clinical | Emory University | Hematologic Neoplasms; Inflammation | Details | |
4S-CAR-FRa | 4S-CAR-FRa | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms | Details |
MOv19-BBz CAR-T cells Therapy | University Of Pennsylvania | Details | |||
Epofolate | BMS-753493 | Bristol-Myers Squibb Company, Novartis Pharma Ag | Details | ||
BAT-8006 | BAT8006; BAT-8006 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Neoplasms | Details |
ITIL-306 | ITIL-306 | Phase 1 Clinical | Instil Bio Inc | Solid tumours; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Genital Neoplasms, Female; Carcinoma, Non-Small-Cell Lung | Details |
ELU-001 | ELU-001 | Phase 2 Clinical | Elucida Oncology Inc | Cholangiocarcinoma; Neoplasm Metastasis; Carcinoma, Endometrioid; Adenocarcinoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Bile Duct Neoplasms; Peritoneal Neoplasms; Breast Neoplasms; Biliary Tract Neoplasms; Klatskin Tumor; Colonic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Ovarian Diseases; Stomach Neoplasms; Rectal Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms; Uterine Diseases | Details |
PRO-1184 | PRO-1184 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Mesothelioma; Breast Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Farletuzumab ecteribulin | MORAb-202 | Phase 2 Clinical | Eisai Co Ltd, Morphotek Inc, Bristol-Myers Squibb Company | Ovarian Neoplasms; Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Luveltamab tazevibulin | SP-7219; DBCO-Alexa647-conjugated SP7219; STRO-002; SP-7675; SP-7676 | Phase 1 Clinical | Sutro Biopharma Inc | Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Endometrioid | Details |
MOv-18 IgE | MOv-18 IgE; MOv18; MOv-18 | Phase 1 Clinical | King'S College London, Cancer Research UK | Ovarian Neoplasms; Neoplasms | Details |
Arfolitixorin | ISO-901; 6R-MTHF | Phase 3 Clinical | Isofol Medical Ab | Rectal Neoplasms; Colonic Neoplasms; Osteosarcoma; Colorectal Neoplasms | Details |
CBP-1008 | CBP-1008 | Phase 2 Clinical | Coherent Biopharma Suzhou Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell | Details |
This web search service is supported by Google Inc.